Myriad Genetics, Inc. (MYGN) Set to Announce Earnings on Monday
Myriad Genetics, Inc. (NASDAQ:MYGN) is set to post its quarterly earnings results after the market closes on Monday, October 30th. Analysts expect Myriad Genetics to post earnings of $0.21 per share for the quarter. Myriad Genetics has set its Q1 guidance at $0.19-0.21 EPS and its FY18 guidance at $1.00-1.05 EPS.
Myriad Genetics (NASDAQ:MYGN) last posted its quarterly earnings data on Tuesday, August 8th. The company reported $0.30 EPS for the quarter, beating the Zacks’ consensus estimate of $0.26 by $0.04. Myriad Genetics had a net margin of 2.83% and a return on equity of 9.67%. The firm had revenue of $200.50 million for the quarter, compared to the consensus estimate of $193.71 million. During the same period in the prior year, the firm posted $0.36 EPS. The firm’s revenue was up 7.5% compared to the same quarter last year. On average, analysts expect Myriad Genetics to post $1.03 EPS for the current fiscal year and $1.19 EPS for the next fiscal year.
Myriad Genetics, Inc. (NASDAQ:MYGN) traded up 0.11% on Monday, reaching $34.90. 160,645 shares of the company’s stock were exchanged. The firm has a 50 day moving average of $34.51 and a 200 day moving average of $26.13. Myriad Genetics, Inc. has a 12 month low of $15.15 and a 12 month high of $37.30. The stock has a market capitalization of $2.39 billion, a PE ratio of 109.40 and a beta of 0.28.
A number of equities analysts recently issued reports on MYGN shares. J P Morgan Chase & Co reaffirmed an “underweight” rating and set a $16.00 target price on shares of Myriad Genetics in a research report on Friday, June 30th. Cowen and Company reaffirmed a “hold” rating and set a $25.00 target price on shares of Myriad Genetics in a research report on Friday, July 14th. Piper Jaffray Companies reaffirmed a “hold” rating and set a $22.00 target price on shares of Myriad Genetics in a research report on Friday, July 14th. Zacks Investment Research raised shares of Myriad Genetics from a “hold” rating to a “buy” rating and set a $28.00 target price on the stock in a research report on Monday, July 17th. Finally, BidaskClub lowered shares of Myriad Genetics from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 19th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating, two have issued a buy rating and one has given a strong buy rating to the stock. Myriad Genetics has a consensus rating of “Hold” and an average target price of $26.40.
In related news, Director John T. Henderson sold 30,000 shares of the stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $30.30, for a total transaction of $909,000.00. Following the completion of the sale, the director now directly owns 52,524 shares of the company’s stock, valued at approximately $1,591,477.20. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 6.70% of the stock is currently owned by corporate insiders.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/10/23/myriad-genetics-inc-mygn-set-to-announce-earnings-on-monday.html.
About Myriad Genetics
Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.
Receive News & Ratings for Myriad Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.